stockrowargenex SE
ARGX Healthcare Biotechnology
argenex SE’s revenue for fiscal 2025 (year ended December 2025) was $4.2 billion, up 88.6% from fiscal 2024.
- Revenue
- +52.1%
- EPS
- +43.9%
- Free cash flow
- +537.5%
Quarter to September 2026, against a year earlier
Follow ARGX
Alert me
argenex SE (ARGX) Shares outstanding
argenex SE's shares outstanding at the end of fiscal 2025 was $66.0M, unchanged from fiscal 2024. At the end of the quarter to 30 September 2026 it was $64.9M. Over the past ten years it has ranged from $18.8M (fiscal 2016) to $66.0M (fiscal 2025) — the current reading is the highest in ten years. argenex SE ranks 235th of 600 Biotechnology companies by shares outstanding.
Shares outstanding, annual
Embed this chart
Annual newest first
| Period | Shares outstanding | Change |
|---|---|---|
| FY2025 | $66.0M | 1.31% |
| FY2024 | $65.2M | 14.01% |
| FY2023 | $57.2M | 5.13% |
| FY2022 | $54.4M | 6.47% |
| FY2021 | $51.1M | 12.48% |
| FY2020 | $45.4M | 17.58% |
| FY2019 | $38.6M | 15.56% |
| FY2018 | $33.4M | 35.79% |
| FY2017 | $24.6M | 30.76% |
| FY2016 | $18.8M | — |
Quarterly newest first
| Period | Shares outstanding | Change |
|---|---|---|
| Sep 2026 | $64.9M | 0.56% |
| Jun 2026 | $64.5M | (2.76%) |
| Mar 2026 | $66.4M | 0.50% |
| Dec 2025 | $66.0M | (0.62%) |
| 25 more quarters | Free account |
Against its own ten years
Shares outstanding against peers
| Company | Shares outstanding |
|---|---|
| ROIV Roivant Sciences Ltd. compare | $720.8M |
| GMAB Genmab A/S Sponsored ADR compare | $617.1M |
| RPRX Royalty Pharma PLC compare | $557.0M |
| MRNA Moderna, Inc. compare | $398.0M |
| RVMD Revolution Medicines, Inc. compare | $214.9M |
| INCY Incyte Corporation compare | $203.2M |
| ONC BeOne Medicines Ltd. - Sponsored ADR compare | $115.8M |
| REGN Regeneron Pharmaceuticals, Inc. compare | $105.6M |
| ARGX argenex SE | $64.9M |
What Shares outstanding is
Shares (Diluted, Weighted) tells an investor how many shares a company’s earnings are spread across once potential new shares are counted.
Reported line item
More on ARGX
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement